On February 1, 2017, the International Association for the Study of Lung Cancer (IASLC) issued the following statement:
“According to its own public reports, in 2016 Phillip Morris manufactured 800 billion cigarettes. Thus, [IASLC] views with some skepticism Philip Morris’ recent statement committing to the design of a smoke-free future (January 25, 2017: Philip Morris International Looks Toward a Smoke-Free Future). While the idea of a ‘smoke-free future’ is something our association of over 5,000 lung cancer specialists worldwide endorses, the statement from Philip Morris notes that the proposed alternatives to tobacco cigarettes are only ‘potentially less harmful’ and makes no concrete commitment to immediate reduction in the manufacture, distribution, and sale of tobacco cigarettes worldwide.
“The IASLC supports real and meaningful efforts to reduce and eliminate the use of tobacco cigarettes worldwide. The development of nicotine delivery products that reliably reduce harm associated with smoking could improve our patients’ lives as long as they are tied to a real commitment to end the sale of conventional cigarettes.
“To demonstrate real and meaningful commitment to a smoke-free future, the IASLC recommends that Philip Morris and its affiliated companies do the following:
“Until then, the IASLC remains committed to tobacco control, to ending the sale of tobacco cigarettes worldwide, and to substantial improvements to the lives of our patients and the future of public health.”
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.